Adicet Bio, Inc.
Adicet Bio, Inc.
Your view on ACET
Overview
What the company does, where it operates, and who runs it.
About Adicet Bio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chen Schor BA, CPA,
- Headquarters
- 200 Clarendon Street, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chen Schor BA, CPA,
- Headquarters
- 200 Clarendon Street, Boston, MA, US
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Adicet Bio, Inc., and the rating behind it. ACET last traded at $9.52; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Adicet Bio, Inc.. Starting points for Adicet Bio, Inc.: EPS -$9.21, beta 1.59 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Adicet Bio, Inc.. Adicet Bio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Adicet Bio, Inc.. Trailing twelve-month EPS for Adicet Bio, Inc. stands at -$9.21. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Adicet Bio, Inc.. Adicet Bio, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Adicet Bio, Inc. valued side by side against its closest peers. Adicet Bio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Adicet Bio, Inc., and how their positions are changing. At a $89.0M market value, institutional positions materially move Adicet Bio, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Adicet Bio, Inc. executives and directors. Shares of Adicet Bio, Inc. have traded between $0.45 and $1.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Adicet Bio, Inc.. Adicet Bio, Inc. is a $89.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Adicet Bio, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Adicet Bio, Inc.. Coverage tracks Adicet Bio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.